Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study

Ziyun Shao, Yongwen Feng, Li Zhong, Qifeng Xie, Ming Lei, Zheying Liu, Conglin Wang, Jingjing Ji, Liu Huiheng, Zhengtao Gu, Zhongwei Hu, Lei Su, Ming Wu, Zhifeng Liu
doi: https://doi.org/10.1101/2020.04.11.20061739
Ziyun Shao
1Department of Nephrology, General Hospital of Central Theater Command of PLA, Wuhan, 430070, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yongwen Feng
2Department of Critical Care Medicine and Hospital Infection Prevention and Control, The Second People’s Hospital of Shenzhen & First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen, 518035, China
3Department of Critical Care Medicine, The Third People’s Hospital of Shenzhen, Shenzhen, 518035, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Li Zhong
4Department of Critical Care Medicine, The First Affiliated Hospital, Guizhou University of Chinese Medicine, Guiyang, 550001, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qifeng Xie
5Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ming Lei
6Department of Nephrology, Guangzhou Eighth people’s hospital, Guangzhou Medical University, Guangzhou,510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zheying Liu
5Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Conglin Wang
5Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jingjing Ji
5Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liu Huiheng
7Department of Emergency, Zhongshan Hospital of Xiamen University, Xiamen, 361000, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhengtao Gu
8Department of Treatment Center for Traumatic Injuries, The Third Affiliated Hospital, Southern Medical University, Academy of Orthopedics Guangdong Province, Guangzhou, Guangdong, 515630, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhongwei Hu
6Department of Nephrology, Guangzhou Eighth people’s hospital, Guangzhou Medical University, Guangzhou,510060, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Zhifengliu7797@163.com boshiyy@126.com slei_icu@163.com gz8hhzw@126.com
Lei Su
5Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Zhifengliu7797@163.com boshiyy@126.com slei_icu@163.com gz8hhzw@126.com
Ming Wu
2Department of Critical Care Medicine and Hospital Infection Prevention and Control, The Second People’s Hospital of Shenzhen & First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen, 518035, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Zhifengliu7797@163.com boshiyy@126.com slei_icu@163.com gz8hhzw@126.com
Zhifeng Liu
5Department of Critical Care Medicine, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China
9Key Laboratory of Hot Zone Trauma Care and Tissue Repair of PLA, General Hospital of Southern Theater Command of PLA, Guangzhou, 510010, China
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Zhifengliu7797@163.com boshiyy@126.com slei_icu@163.com gz8hhzw@126.com
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance Coronavirus disease 2019 (COVID-19) has become pandemic, causing more than 1.5 million infections and over ten-thousands of deaths in a short period of time worldwide. However, little is known about its pathological mechanism, and reports on clinical study on specific treatment are few.

Objective The purpose of this study is to determine the clinical efficacy of intravenous immunoglobulin (IVIG) therapy in COVID-19 patients.

Design, setting and participants This multicenter retrospective cohort study enrolled 325 adult critical COVID-19 patients, including severe type and critical type, according to the clinical classification defined by National Health Commission of China, in 8 government designated treatment centers in China from Dec 23, 2019 to Mar 31, 2020. Demographic, clinical, treatment, and laboratory data as well as prognosis were extracted from electronic medical records.

Exposure IVIG was exposure factor.

Main outcomes and measures Primary outcomes were the 28-day and 60-day mortality, and secondary outcomes were the total length of in-hospital and the total duration of the disease. Meanwhile, the parameters of inflammation responses and organ functions were measured. The risk factors were determined by COX proportional hazards model. The subgroup analysis was carried out according to clinical classification of COVID-19, IVIG dosage, and timing.

Results In the enrolled 325 patients, 222 (68%) were severe type and 103 (32%) were critical type; 42 (13%) died in 28-day within hospitalization, and 54 (17%) died within 60-day; The death in 60-day includes 6 (3%) severe type patients and 48 (47%) critical type patients. 174 cases were used IVIG, and 151 cases were not. Compared with the baseline characteristics between two groups, the results showed that the patients in IVIG group presented higher Acute Physiology and Chronic Health Evaluation (APACHII) score and Sequential Organ Failure Assessment (SOFA) score, higher plasm levels of IL-6 and lactate, and lower lymphocyte count and oxygenation index (all P<0.05). The 28-day and 60-day mortality were not improved with IVIG in overall cohort. The in-hospital stay and the total duration of disease were longer in IVIG group (P<0.001). Risk factors were clinical classifications (hazards ratio 0.126, 95% confidence interval 0.039-0.413, P=0.001), and using IVIG (hazards ratio 0.252, 95% confidence interval 0.107-0.591, P=0.002) with COX proportional hazards model. Subgroup analysis showed that only in patients with critical type, IVIG could significantly reduce the 28-day mortality, decrease the inflammatory response, and improve some organ functions (all P<0.05); and application of IVIG in the early stage (admission≤7 days) with a high dose (>15 g/d) exhibited significant reduction of 60-day mortality in the critical type patients.

Conclusions and Relevance Early administration of IVIG with high dose improves the prognosis of critical type patients with COVID-19. This study provides important information on clinical application of the IVIG in treatment of SARS-CoV-2 infection, including patient selection and administration timing and dosage.

Question Intravenous immunoglobulin (IVIG) was recommended to treat critical Coronavirus disease 2019 (COVID-19) patients in a few reviews, but the clinical study evidence on its efficacy in COVID-19 patients was lacked.

Finding In this multicenter cohort study that included 325 adult critical patients from 8 treatment centers, the results showed that early administration (admission ≤ 7 days) of IVIG with high dose (> 15 g/d) improves the prognosis of critical type patients with COVID-19.

Meaning This study provides important information on clinical application of IVIG in treatment of SARS-CoV-2 infection, including patient selection, administration timing and dosage.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NA

Funding Statement

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data sets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 20, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study
Ziyun Shao, Yongwen Feng, Li Zhong, Qifeng Xie, Ming Lei, Zheying Liu, Conglin Wang, Jingjing Ji, Liu Huiheng, Zhengtao Gu, Zhongwei Hu, Lei Su, Ming Wu, Zhifeng Liu
medRxiv 2020.04.11.20061739; doi: https://doi.org/10.1101/2020.04.11.20061739
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Clinical Efficacy of Intravenous Immunoglobulin Therapy in Critical Patients with COVID-19: A Multicenter Retrospective Cohort Study
Ziyun Shao, Yongwen Feng, Li Zhong, Qifeng Xie, Ming Lei, Zheying Liu, Conglin Wang, Jingjing Ji, Liu Huiheng, Zhengtao Gu, Zhongwei Hu, Lei Su, Ming Wu, Zhifeng Liu
medRxiv 2020.04.11.20061739; doi: https://doi.org/10.1101/2020.04.11.20061739

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Intensive Care and Critical Care Medicine
Subject Areas
All Articles
  • Addiction Medicine (269)
  • Allergy and Immunology (549)
  • Anesthesia (134)
  • Cardiovascular Medicine (1747)
  • Dentistry and Oral Medicine (238)
  • Dermatology (172)
  • Emergency Medicine (310)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (653)
  • Epidemiology (10780)
  • Forensic Medicine (8)
  • Gastroenterology (584)
  • Genetic and Genomic Medicine (2933)
  • Geriatric Medicine (286)
  • Health Economics (531)
  • Health Informatics (1918)
  • Health Policy (833)
  • Health Systems and Quality Improvement (743)
  • Hematology (290)
  • HIV/AIDS (627)
  • Infectious Diseases (except HIV/AIDS) (12496)
  • Intensive Care and Critical Care Medicine (684)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (321)
  • Neurology (2780)
  • Nursing (150)
  • Nutrition (431)
  • Obstetrics and Gynecology (554)
  • Occupational and Environmental Health (597)
  • Oncology (1454)
  • Ophthalmology (440)
  • Orthopedics (172)
  • Otolaryngology (255)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (379)
  • Pediatrics (865)
  • Pharmacology and Therapeutics (362)
  • Primary Care Research (333)
  • Psychiatry and Clinical Psychology (2630)
  • Public and Global Health (5338)
  • Radiology and Imaging (1002)
  • Rehabilitation Medicine and Physical Therapy (594)
  • Respiratory Medicine (722)
  • Rheumatology (329)
  • Sexual and Reproductive Health (288)
  • Sports Medicine (278)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (149)
  • Urology (125)